IP Verse

Deuterated Derivatives Of Ruxolitinib - EP3450434

The patent EP3450434 was granted to Concert Pharmaceuticals on Feb 24, 2021. The application was originally filed on Jun 14, 2013 under application number EP18188152A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3450434

CONCERT PHARMACEUTICALS
Application Number
EP18188152A
Filing Date
Jun 14, 2013
Status
Granted And Under Opposition
Jan 22, 2021
Grant Date
Feb 24, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

INCYTENov 23, 2021CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006079502
DESCRIPTIONUS2006094744
DESCRIPTIONUS2008312258
DESCRIPTIONUS5304121
DESCRIPTIONUS5886026
DESCRIPTIONUS6099562
DESCRIPTIONUS6803031
DESCRIPTIONUS7014866
DESCRIPTIONUS7598257
DESCRIPTIONWO2010083283
EXAMINATIONWO2014078486
OPPOSITIONUS2007135461
OPPOSITIONUS7855204
OPPOSITIONWO2013188783
SEARCHUS2007135461

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BLAKE, MI et al., J Pharm Sci, (19750000), vol. 64, pages 367 - 91-
DESCRIPTION- FISHER, MB et al., Curr Opin Drug Discov Devel, (20060000), vol. 9, pages 101 - 09-
DESCRIPTION- FOSTER, AB, Adv Drug Res, (19850000), vol. 14, pages 1 - 40-
DESCRIPTION- FREIREICH et al., Cancer Chemother. Rep, (19660000), vol. 50, page 219-
DESCRIPTION- FUKUTO et al., J. Med. Chem., (19910000), vol. 34, pages 2871 - 76-
DESCRIPTION- GANNES, LZ et al., Comp Biochem Physiol Mol Integr Physiol, (19980000), vol. 119, page 725-
DESCRIPTION- KEMPF, D.J. et al., Antimicrobial agents and chemotherapy, (19970000), vol. 41, no. 3, pages 654 - 60-
DESCRIPTION- KUSHNER, DJ et al., Can J Physiol Pharmacol, (19990000), pages 79 - 88-
DESCRIPTION- LIN, Q. et al., Org. Lett., (20090000), vol. 11, page 1999-
DESCRIPTION- LIN, Q. et al., Org. Lett., (20090000), vol. 11, pages 1999 - 2002-
DESCRIPTION- Organic Letters, (20090000), vol. 11, no. 9, pages 1999 - 2009-
DESCRIPTION- Scientific Tables, Geigy Pharmaceuticals, (19700000), page 537-
DESCRIPTION- SHILLING, A.D. et al., Drug Metabolism and Disposition, (20100000), vol. 38, no. 11, pages 2023 - 2031-
DESCRIPTION- WADA, E et al., Seikagaku, (19940000), vol. 66, page 15-
DESCRIPTION- WANG, L et al., Clinical Pharmacology and Therapeutics, (19940000), vol. 56, no. 6, pages 659 - 67-
EXAMINATION- EMA/465846/2012: CHMP assessment report for Jakavi, 19 April 2012, 84 pages.-
EXAMINATION- "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients", (20110422), URL: https://clinicaltrials.gov/ct2/show/NCT01340651-
OPPOSITION- A. YARNELL, "Heavy-Hydrogen Drugs Turn Heads, Again", Chem. Eng. News, (20090000), vol. 87, no. 25, pages 36 - 39, XP002546075-
OPPOSITION- BUTEAU K C, "Deuterated Drugs: Unexpectedly Nonobvious?", JOURNAL OF HIGH TECHNOLOGY LAW, SUFFOLK UNIVERSITY LAW SCHOOL,, US, US , (20090101), vol. X, no. 1, ISSN 1536-7983, pages 22 - 74, XP002636702-
OPPOSITION- A. D. Shilling, F. M. Nedza, T. Emm, S. Diamond, E. Mckeever, N. Punwani, W. Williams, A. Arvanitis, L. G. Galya, M. Li, S. Shepard, J. Rodgers, T.-Y. Yue, S. Yeleswaram, "Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans", Drug Metabolism and Disposition, ¬American Society for Pharmacology and Experimental Therapeutics, etc.|, (20101101), vol. 38, no. 11, doi:10.1124/dmd.110.033787, ISSN 00909556, pages 2023 - 2031, XP055071854
OPPOSITION- Ostojic Alen; Vrhovac Radovan; Verstovsek Srdan, "Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, GB , (20110101), vol. 7, no. 9, doi:10.2217/fon.11.81, ISSN 1479-6694, pages 1035 - 1043, XP008150477
SEARCH- BUTEAU, "Deuterated Drugs: Unexpectedly Nonobvious?", vol. X, no. 1, ISSN 1536-7983, (20090101), pages 22 - 74, JOURNAL OF HIGH TECHNOLOGY LAW, SUFFOLK UNIVERSITY LAW SCHOOL, US, URL: http://www.law.suffolk.edu/highlights/stuorgs/jhtl/docs/pdf/Buteau_10JHTL1.pdf, (20090101), XP002636702 [L] 1-12 * Page 62, footnotes 248, 249 on predictability and obviousness; paragraph bridging pages 64-65; page 69, paragraph 2; page 72, last sentence to page 73, end of paragraph 1. Cited as common general knowledge. *-
SEARCH- SHILLING ET AL., "Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans", DRUG METABOLISM AND DISPOSITION, (20101101), vol. 38, no. 11, doi:10.1124/dmd.110.033787, ISSN 0090-9556, pages 2023 - 2031, XP055071854 [YD] 1-12 * Page 2016, right column 1st sentence; page 2028, figure 2; page 2030, left column to right column, paragraph 1. *
SEARCH- OSTOJIC ET AL., "Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis", FUTURE ONCOLOGY, (20110101), vol. 7, no. 9, doi:10.2217/FON.11.81, ISSN 1479-6694, pages 1035 - 1043, XP008150477 [Y] 1-12 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents